NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity

In a groundbreaking study published in Nature, Heide, Bilecz, Patnaik, and colleagues revealed a previously unknown role for NNMT (nicotinamide N-methyltransferase) in enabling tumors to evade the immune system. This discovery positions NNMT inhibitors as potential game-changers not only in metabolic health but also in cancer immunotherapy.

The researchers investigated how cancer-associated fibroblasts — the supportive cells that tumors recruit to build their protective microenvironment — use NNMT to suppress anti-tumor immune responses. They tested whether pharmacological NNMT inhibition could reverse this immunosuppressive effect and restore the body's natural ability to fight cancer.

The results were striking: NNMT inhibition in cancer-associated fibroblasts dramatically restored anti-tumor immunity. By blocking NNMT, the researchers were able to reprogram the tumor microenvironment from immunosuppressive to immunostimulatory, enabling immune cells to recognize and attack cancer cells that had previously been shielded from immune surveillance.

This Nature publication represents a landmark moment for the NNMT inhibitor field. While compounds like 5-Amino-1MQ have been primarily studied for their metabolic benefits in fat metabolism and body composition, this research reveals that NNMT plays a far broader biological role than previously appreciated. The potential for NNMT inhibitors to enhance cancer immunotherapy adds an entirely new dimension to their therapeutic value.